Rule 3.19A.3

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: Universal Biosensors, Inc.	
ABN: 121 559 993	

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	John Sharman
Date of last notice	17 January 2025
Date that director ceased to be director	1 April 2025

Part 1 – Director's relevant interests in securities of which the director is the registered holder *In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
103,055 CDIs (equivalent to 103,055 fully paid ordinary shares).
23,055 quoted options with an expiry date of 8 May 2027 and an exercise price of \$0.2 per option.

⁺ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
J S Super Fund (John Sharman is the trustee and beneficiary)	394,666 CDIs (equivalent to 394,666 fully paid ordinary shares).
	30,000 quoted options with an expiry date of 8 May 2027 and an exercise price of \$0.20 per option.
Amira Sharman (spouse)	1,561,217 CDIs (equivalent to 1,561,217 fully paid ordinary shares).
	10,000 quoted options with an expiry date of 8 May 2027 and an exercise price of \$0.20 per option.

Part 3 – Director's interests in contracts

_

Appendix 3Z Page 2 11/3/2002

⁺ See chapter 19 for defined terms.